Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib plus whole brain radiotherapy in metastatic melanoma with brain metastases
ISRCTN20253034Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Dec 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in melanoma and brain metastases (3 arms), sponsored by University of Oxford. Primary endpoint: Progression-free survival in brain. Started Dec 2011; status: completed.
02
Drugs
vandetanib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on ISRCTN20253034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN20253034.